Lamivudine, Nevirapine, and Zidovudine
- Product NDC
- 42571-166
- 11-digit product format
- 425710166
- Labeler code
- 42571
- Product ID
- 42571-166_73d82e59-0f5b-0502-e053-2a91aa0a3f52
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Lamivudine, Nevirapine, and Zidovudine
- Dosage form
- TABLET, FILM COATED
- Route
- ORAL
- Labeler
- Micro Labs Limited
- Application
- NDA205626
- Marketing category
- NDA
- Marketing start
- 2018-09-03
- Marketing end
- 0000-00-00
- Substance
- LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE
- Active strength
- 150 mg/1; mg/1; mg/1
- Pharmacologic classes
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Non-Nucleoside Analog [EXT],Non-Nucleoside Reverse Transcriptase Inhibitors [MoA],Cytochrome P450 3A Inducers [MoA],Cytochrome P450 2B6 Inducers [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2019-12-31
- Current FDA listing
- Historical FDA.report record